Emerging paradigms in GPCR allostery: implications for drug discovery

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Allosteric ligands bind to G protein-coupled receptors (GPCRs; also known as seven-transmembrane receptors) at sites that are distinct from the sites to which endogenous ligands bind. The existence of allosteric ligands has enriched the ways in which the functions of GPCRs can be manipulated for potential therapeutic benefit, yet the complexity of their actions provides both challenges and opportunities for drug screening and development. Converging avenues of research in areas such as biased signalling by allosteric ligands and the mechanisms by which allosteric ligands modulate the effects of diverse endogenous ligands have provided new insights into how interactions between allosteric ligands and GPCRs could be exploited for drug discovery. These new findings have the potential to alter how screening for allosteric drugs is performed and may increase the chances of success in the development of allosteric modulators as clinical lead compounds.
Original languageEnglish
Pages (from-to)630 - 644
Number of pages15
JournalNature Reviews Drug Discovery
Volume12
Issue number8
DOIs
Publication statusPublished - 2013

Cite this

@article{2863b607650e44bfb37e5b7b9b08a59b,
title = "Emerging paradigms in GPCR allostery: implications for drug discovery",
abstract = "Allosteric ligands bind to G protein-coupled receptors (GPCRs; also known as seven-transmembrane receptors) at sites that are distinct from the sites to which endogenous ligands bind. The existence of allosteric ligands has enriched the ways in which the functions of GPCRs can be manipulated for potential therapeutic benefit, yet the complexity of their actions provides both challenges and opportunities for drug screening and development. Converging avenues of research in areas such as biased signalling by allosteric ligands and the mechanisms by which allosteric ligands modulate the effects of diverse endogenous ligands have provided new insights into how interactions between allosteric ligands and GPCRs could be exploited for drug discovery. These new findings have the potential to alter how screening for allosteric drugs is performed and may increase the chances of success in the development of allosteric modulators as clinical lead compounds.",
author = "Wootten, {Denise Laura} and Arthur Christopoulos and Patrick Sexton",
year = "2013",
doi = "10.1038/nrd4052",
language = "English",
volume = "12",
pages = "630 -- 644",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "8",

}

Emerging paradigms in GPCR allostery: implications for drug discovery. / Wootten, Denise Laura; Christopoulos, Arthur; Sexton, Patrick.

In: Nature Reviews Drug Discovery, Vol. 12, No. 8, 2013, p. 630 - 644.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Emerging paradigms in GPCR allostery: implications for drug discovery

AU - Wootten, Denise Laura

AU - Christopoulos, Arthur

AU - Sexton, Patrick

PY - 2013

Y1 - 2013

N2 - Allosteric ligands bind to G protein-coupled receptors (GPCRs; also known as seven-transmembrane receptors) at sites that are distinct from the sites to which endogenous ligands bind. The existence of allosteric ligands has enriched the ways in which the functions of GPCRs can be manipulated for potential therapeutic benefit, yet the complexity of their actions provides both challenges and opportunities for drug screening and development. Converging avenues of research in areas such as biased signalling by allosteric ligands and the mechanisms by which allosteric ligands modulate the effects of diverse endogenous ligands have provided new insights into how interactions between allosteric ligands and GPCRs could be exploited for drug discovery. These new findings have the potential to alter how screening for allosteric drugs is performed and may increase the chances of success in the development of allosteric modulators as clinical lead compounds.

AB - Allosteric ligands bind to G protein-coupled receptors (GPCRs; also known as seven-transmembrane receptors) at sites that are distinct from the sites to which endogenous ligands bind. The existence of allosteric ligands has enriched the ways in which the functions of GPCRs can be manipulated for potential therapeutic benefit, yet the complexity of their actions provides both challenges and opportunities for drug screening and development. Converging avenues of research in areas such as biased signalling by allosteric ligands and the mechanisms by which allosteric ligands modulate the effects of diverse endogenous ligands have provided new insights into how interactions between allosteric ligands and GPCRs could be exploited for drug discovery. These new findings have the potential to alter how screening for allosteric drugs is performed and may increase the chances of success in the development of allosteric modulators as clinical lead compounds.

UR - http://www.nature.com/nrd/journal/v12/n8/pdf/nrd4052.pdf

U2 - 10.1038/nrd4052

DO - 10.1038/nrd4052

M3 - Article

VL - 12

SP - 630

EP - 644

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 8

ER -